2025 Agenda

• Exploring how strategic partnerships accelerate the adoption of new manufacturing capabilities and technologies

• Highlighting how collaboration enables agility, from early development through commercial scale

• Discussing how flexible partnership models can help biopharma companies navigate shifting market and regulatory pressures

• Announcement of the Biotech Incentive Program, designed for early-stage cell therapy developers to extend your runway
• Leverage integrated manufacturing / QC automation and regulatory-ready infrastructure to accelerate clinical timelines
• Recoup costs through lower batch price, commercial scale throughput and operation efficiency

Pharmaceutical Supply Chains are under pressure from a myriad of angles.  Demand volatility, external capacity constraints, complex modalities with longer lead times, evolving regulatory landscape, geopolitical tension and pricing/tariff pressure are just some of the dynamics which require new ways of working.  Supporting reliable supply to customers and patients while maintaining efficient levels of inventory requires a step-change in the way that the planning function interacts with internal Operations and CMO’s.  J&J will lead a conversation with Bluecrux, sharing lessons learned through several practical examples in the area of Plan-to-Plant synchronization.  Key to J&J’s ascent into Gartner’s Top 5 Supply Chains, these advancements in maturity are buoyed by a holistic approach across People/Process/Technology under the Advance Planning Transformation umbrella.

• Establishing agile technical operations in an ever-changing environment
• Building trusted internal and external partnerships
• Strategies to maximize innovation and manufacturing efficiency
• Planning for the Future – Balancing quality and speed to market

• Challenges and trends facing the industry
• Tackling the ever-growing complexity of the industry
• Most critical outcomes and value in solving the challenges
• AI is not the answer for everything, but it sure can help

• Monoclonal antibodies (mAb) have demonstrated clinical efficacy, but their high cost restricts widespread patient access
• The cost of goods (COGs) for manufacturing mAbs sets the lower boundary of price
• BiBo’s 30kL ultra-large mammalian production platform delivers a scalable solution to significantly reduce mAb manufacturing costs while ensuring adequate and robust supply capacity